Navigation Links
Clarient Announces Fourth Quarter and Year-End 2007 Financial Results
Date:3/31/2008

Quarterly Revenue and Case Volumes Increase 53% and 52% Respectively

Year-over-Year

ALISO VIEJO, Calif., March 31 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced financial results for the fourth quarter and year ended December 31, 2007. Revenue from continuing operations was $12.4 million for the fourth quarter of 2007, an increase of over 53 percent compared to $8.1 million for the comparable period in 2006.

Total patient case volume for the fourth quarter of 2007 was approximately 21,500, an increase of 52 percent compared to the comparable period in 2006. Sequential total patient test volume in comparison to the third quarter of 2007 increased 10 percent, including a 6 percent increase in breast prognostics/solid tumor testing, an 18 percent increase in leukemia/lymphoma volumes, and a 12 percent increase in PCR/molecular testing volumes.

Clarient reported $6.4 million in gross profit for the fourth quarter of 2007, an increase of 78 percent as compared to $3.6 million for the comparable period in 2006. Reported gross margin in the fourth quarter of 2007 was 52 percent as compared to 45 percent for the same period 2006. Gross margins improved as a result of increased total patient volume, better use of the Company's capacity, improved revenue mix, improved process efficiencies and improved pricing with vendors.

Commenting on the year end results, Ron Andrews, President and CEO, said, "Our business model continued to validate that we can produce sustainable growth as we completed the quarter with a 53 percent increase in revenue over the fourth qua
'/>"/>

SOURCE Clarient, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
2. Clarient to Commercialize Novel Breast Cancer Profile
3. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today announced ... a leading Russian pharmaceutical company, to develop and commercialize ... Federation , Turkey and ... a novel antibiotic for the treatment of bacterial infections ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging ... to serve the wound care market. , Free report ... was restructured with a seasoned management team and Board, ...
(Date:1/14/2014)... 2014 iLab Solutions, the leader in core ... Director of Product Strategy. In this role, Michelle will work ... to guide in the development of iLab products. Her main ... possible benefit to the scientific community by offering the most ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... , EMERYVILLE, Calif., Aug. 6 Onyx Pharmaceuticals, ... to sell an aggregate of four million shares of its common stock ... million aggregate principal amount of its 4.00% convertible senior notes due 2016 ... options to purchase up to an additional 600,000 shares of its common ...
... , ALBANY, Ore., Aug. 6 Synthetech, Inc. (OTC ... of fiscal 2010, which ended June 30, 2009. Revenue for ... of $4.9 million in the first quarter of fiscal 2009. ... operating income of $314,000 for the same period last year. ...
... Md., Aug. 6 Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: ... of clinical-stage product candidates for central nervous system disorders, today announced ... on Monday, August 10, 2009, before the market opens. A full ... , , Mihael H. Polymeropoulos, M.D., President and ...
Cached Biology Technology:Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes 2Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes 3Synthetech Reports First Quarter Fiscal 2010 Results 2Synthetech Reports First Quarter Fiscal 2010 Results 3Synthetech Reports First Quarter Fiscal 2010 Results 4Synthetech Reports First Quarter Fiscal 2010 Results 5Synthetech Reports First Quarter Fiscal 2010 Results 6Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009 2
(Date:4/24/2014)... It,s broadly understood that the world,s oceans play ... exchange of carbon between Earth,s ecosystems and atmosphere. ... UC San Diego have taken a leap forward ... , When phytoplankton use carbon dioxide to make ... material is released into the sea as a ...
(Date:4/24/2014)... COLUMBIA, Mo. When bacteria attack plants, they ... cells to weaken and suppress natural defenses. However, ... the plant cells as a potential host. Now, ... and replicated the process that allows the bacteriaknown ... discovery could lead to natural anti-infective treatments that ...
(Date:4/24/2014)... April 24, 2014GEN Publishing recently introduced ... focusing on the application of OMICs technologies in ... sequencing, are beginning to transform medical care just ... the past decade-and-a-half. , "GEN,s editors and reporters ... genomics, metabolomics, transcriptomics, etc. etc. for years," said ...
Breaking Biology News(10 mins):Microscopic organism plays a big role in ocean carbon cycling, Scripps scientists discover 2Microscopic organism plays a big role in ocean carbon cycling, Scripps scientists discover 3Plants send out signals attracting harmful bacteria, MU study finds 2
... Mellon University,s Philip R. LeDuc and his collaborators in ... a protein that could ultimately unlock the mystery of ... role in the mechanics of biological processes in people. ... function of a protein that helps control cell behavior ...
... Reunion in the Indian Ocean and collaborating with researchers at ... sensitive night cameras to capture the first known occurrence of ... only is this the first time this behaviour has been ... who are better known for eating plants but ...
... number of scientists are merging methods and results from different ... team of researchers in a recent issue of Evolution ... new data, however, researchers who want to analyze previous findings ... the authors say. In a commentary piece in the journal ...
Cached Biology News:Carnegie Mellon's Philip LeDuc discovers new protein function 2First known instance of a cricket as an orchid pollinator captured on film by Kew scientist 2Biologists merge methods, results from different disciplines to find new meaning in old data 2Biologists merge methods, results from different disciplines to find new meaning in old data 3
Application: for RNase- decontamination , Registered Trademark of Ambion. ,Special grade: for molecular biology Density: 1.00 g/mL (20 C) Suitab tst: RNase decontamination in accordance...
With L-glutamine and potassium bicarbonate. Sterile, Insect cell culture tested...
... meet the needs of the ... medium supports fast cell growth ... while maintaining high cell viability ... using the Baculovirus Expression Vector ...
Mol wt: average mol wt12,360.96 Da by calculation...
Biology Products: